The newly authorized platform can be used in a range of minimally invasive soft-tissue procedures. Approved indications include Roux-en-Y gastric bypass, gastrectomy, sleeve gastrectomy, cholecystectomy, splenectomy, appendectomy, small bowel resection, lysis of adhesions, fundoplication, and hiatal hernia repair.

Company executives described the authorization as a milestone that could help advance robotic-assisted surgery and improve surgical care delivery. Johnson & Johnson views the system as more than a new device, positioning it as a platform designed to support future innovations in the operating room.

Limited Commercial Introduction Planned

Rather than immediately pursuing a broad market launch, the company plans a phased U.S. introduction with a select group of healthcare providers. The strategy is intended to generate early clinical and operational experience while the company continues to expand regulatory approvals and pursue additional surgical applications.

One area of ongoing development is inguinal hernia repair. The Ottava system is currently being evaluated for that indication in a U.S. clinical trial.

Design Focuses on Operating Room Efficiency

A key differentiator for Ottava is its integrated design. The system incorporates four robotic arms directly into a standard-sized surgical table, eliminating the need for separate floor-mounted carts or overhead booms commonly associated with some robotic platforms.

According to Johnson & Johnson, this approach enables the system to fit into a wider variety of operating rooms while helping preserve valuable floor space. The design may appeal to hospitals seeking robotic surgery capabilities without major changes to existing surgical suites.

Entering a Crowded and Established Market

With FDA authorization secured, Ottava enters a competitive landscape dominated by Intuitive Surgical’s da Vinci platform, which has long held a leading position in robotic-assisted surgery. Other competitors include Medtronic and CMR Surgical, both of which have introduced systems aimed at expanding surgeon choice and increasing competition in the field.

Despite Ottava’s novel features, some market analysts believe established platforms retain a strong advantage. In a note to investors, J.P. Morgan analyst Robbie Marcus highlighted Intuitive Surgical’s deep physician relationships, extensive hospital integration, and presence in academic training programs as factors that continue to support the da Vinci system’s market leadership.

Outlook

FDA clearance represents an important achievement for Johnson & Johnson after years of development of the Ottava platform. The company’s gradual rollout strategy suggests a focus on demonstrating clinical value and user adoption before broader commercialization. As additional indications are pursued and real-world experience accumulates, the system’s performance will be closely watched by hospitals, surgeons, and investors as competition in surgical robotics continues to intensify.